Navigation Links
Novavax Reports Second Quarter 2009 Financial Results

oration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                                   NOVAVAX, INC.
               (in thousands, except share and per share information)

                                    Three months ended      Six months ended
                                        June 30,                June 30,
                                        --------                --------
                                    2009      2008          2009       2008
                                    ----      ----          ----       ----
    Revenues                           29        342           50         800
                                       --        ---           --         ---

    Operating costs and
       Research and development     5,297      5,380        9,563     
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
(Date:3/29/2015)... As a symbol of its commitment ... pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to announce ... Race Team for the 2015 race season. Success on ... a strong sense of precision and attention to detail. ... in the quality control testing laboratory. Sponsorship of the ...
(Date:3/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... prearranged trading plan in accordance with Securities and Exchange ... CEO of Neogen Corporation, is a minority owner of ... stock. Herbert does not have control of ... filing is only for a portion of the shares ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
Breaking Biology Technology:Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Neogen CEO adopts 10b5-1 Trading Plan 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... Replikins Ltd. published a FluForecast(R) warning in April 7th, ... H1N1 cases. The company was able to state the ... Count(TM) genomics technology, which examines specific regions in virus ... 2008 announcement, attached below as published on the Web, ...
... cells to combat aging and help support healing , ... ... Aesthetics , a division of Histogen focused on providing unique, clinically ... launch of the ReGenica™ Rejuvenation System for anti-aging and post-resurfacing. ...
... Mass., April 27 LaVoie Group, a life science-focused ... selected as investor relations agency of record for Pegasus ... LaVoie Group, commented, "Pegasus has the opportunity to capture ... The Company is changing the standard of care in ...
Cached Biology Technology:Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak 2Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak 3Histogen Aesthetics Launches ReGenica Rejuvenation System 2Histogen Aesthetics Launches ReGenica Rejuvenation System 3Histogen Aesthetics Launches ReGenica Rejuvenation System 4LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster 2
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... burn crop residues and get the land ready for ... image from the MODIS instrument on the Aqua satellite. ... fires can be found at this URL: ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua ...
... genes to living human tissue, the odds of success come ... used to bring new genetic material into a cell ... process will simplify non-viral transfection, providing a method researchers and ... deliver genes to cells. Developed by William Murphy, ...
... led by Dr. Suresh Alahari, Professor of Biochemistry and Molecular ... first to report that two specific tumor suppressor genes work ... tumor cells to the lungs. The research is published this ... Working in a mouse model, the LSUHSC research team studied ...
Cached Biology News:Material screening method allows more precise control over stem cells 2LSUHSC research discovers new drug target for metastatic breast cancer 2
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: